Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Uterine Cervical Neoplasms 1Multiple Myeloma 1Histologically-confirmed Malignancies 1

Interventions

Dexamethasone 45Bortezomib 19Lenalidomide 18Calcium Dobesilate 18Melphalan 16Cyclophosphamide 11pomalidomide 10daratumumab 9elotuzumab 8carfilzomib 8pembrolizumab 6ixazomib 6fludarabine phosphate 6dexamethasone acetate 6fludarabine 5dexamethasone 21-phosphate 5Filgrastim 5venetoclax 4selinexor 4auricularum 4Thalidomide 4Tacrolimus 4Peripheral Blood Stem Cell Transplantation 4Magnetic Resonance Spectroscopy 4liposomal doxorubicin 3Whole-Body Irradiation 3Vorinostat 3Nivolumab 3Mycophenolic Acid 3Leukapheresis 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Multiple Myeloma × Positron Emission Tomography Computed Tomography × Clear all
NCT04467281 2022-07-01

A Study of PET/CT Scans With the Radioactive Tracer 89Zr-DFO-Daratumumab in People With Myeloma

Memorial Sloan Kettering Cancer Center

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡